x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

CME/CE

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD"s CME activities. Our topics span cardiology, diabetes, oncology, women"s health and more. And our CME library is continuously growing, every quarter.

science & medicine medicine

All Episodes

00:00:00

Insights and Updates: New Data on Next-Generation...

CME/CE ·

2025/09/02

Faculty: Durga Borkar, MD, MMCi Faculty: Veeral Sheth, MD, MBA, FASRS, FACS Need to catch up on the latest data surrounding next-generation retinal treatments? Drs. Veeral Sheth and Durga Borkar walk through the most recent efficacy and safety data around faricimab, aflibercept 8 mg, and the PDS with ranibizumab. They also review the latest insights on the use of these treatments in real-world practice.

en

00:00:00

Advancing Research and Novel Therapies for C3G

CME/CE ·

2025/09/02

In this episode of KDIGO Conversations in Nephrology, Dr. Carla Nester is joined by Dr. Nicole van de Kar, Professor of Pediatrics at Radboud University Medical Center in the Netherlands, to discuss the role of complement in C3 glomerulopathy (C3G). They begin by defining C3G and exploring its pathophysiology, specifically focusing on the overactivation of the alternative pathway of the complement system.Then, Drs. Nester and van de Kar delve into the specifics of why the alternative

en

00:00:00

Diagnosis and Management of C3G

CME/CE ·

2025/09/02

In this episode of KDIGO Conversations in Nephrology, Dr. Carla Nester is joined by Dr. David Kavanagh, Professor of Complement Therapeutics at the National Renal Complement Therapeutic Centre in Newcastle, England, to discuss the diagnosis and management of C3 glomerulopathy (C3G). They cover how patients present and the diagnostic workup required to confirm the diagnosis and rule out other diseases that can mimic C3G. The discussion also focuses on the current and future treatment

en

00:00:00

Complement Mediated Kidney Disease Series - A Patient...

CME/CE ·

2025/09/02

In this episode of KDIGO Conversations in Nephrology, Dr. Carla Nester is joined by Marianne Silkjaer Nielsen. Not only is Ms. Nielsen the mother of a girl who lives with immune complex-MPGN, but she’s also the founder of CompCure, a not-for-profit association that is dedicated to improving outcomes in patients with C3G and immune complex-MPGN. Together, their conversation will cover: The Diagnostic Journey: Rare diseases often have a long diagnostic journey. A specialized pathologist

en

00:00:00

The Role of the Complement System in Kidney Diseases

CME/CE ·

2025/09/02

In this episode of KDIGO Conversations in Nephrology, Dr. Carla Nester, Professor of Internal Medicine and Pediatrics at the University of Iowa's Stead Family Children's Hospital, is joined by Dr. Matthew Pickering, Professor of Rheumatology at Imperial College London. Together, Drs. Nester and Pickering discuss the role of the complement system in complement-driven versus complement-associated kidney diseases and the clinical implications of this distinction. They explore the pros and

en

00:00:00

Molecular Magic: Decoding the Unique Mechanism of...

CME/CE ·

2025/08/21

Faculty: Noopur Raje, MD Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate

en

00:00:00

Precision Targeting: Matching CELMoDs to the Right...

CME/CE ·

2025/08/21

Faculty: Sagar Lonial, MD, FACP Faculty: Noopur Raje, MD Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other

en

00:00:00

Breaking New Ground: Acoramidis Reduces AF Events in...

CME/CE ·

2025/08/08

Faculty: Kevin Alexander, MD This brief clinical discussion examines findings presented at the ESC Heart Failure 2025 meeting in Belgrade, Serbia, on the impact of acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM). The analysis highlights a reduction in atrial fibrillation events and an improvement in cardiovascular outcomes among patients treated with acoramidis, including those with both wild-type and variant transthyretin (TTR). Data from the ATTRibute-CM study are

en

00:00:00

Continuity in Care: Strategies for Managing Growth...

CME/CE ·

2025/08/05

Host: Aristides Maniatis, MD Guest: Kari Hosack Guest: Meagan Broeckert Guest: Sam Watson Join Dr. Aristides Maniatis for this Patient-Clinician Connection, a case-based activity that explores the full spectrum of care in Growth Hormone Deficiency. Through real patient and caregiver dialogues, this program teaches clinicians how to identify early signs of GHD, make accurate diagnoses, navigate pediatric-to-adult care transitions, and manage the switch from daily to

en

00:00:00

Chairperson’s Perspective: Optimizing Perioperative...

CME/CE ·

2025/08/01

Guest: Heather Wakelee, MD, FASCO Perioperative immunotherapy has evolved into a novel therapeutic strategy for early-stage, resectable NSCLC, maximizing the efficacy of immunotherapy when the primary tumor is still present with a high neoantigen burden. Perioperative immunotherapy also allows the use of preoperative pathology as a guide for postoperative care and offers a pathway to potential surgical intervention due to tumor shrinkage for those who are not initially eligible for

en

00:00:00

TTR Levels and Associated Disease Risk: Insights from...

CME/CE ·

2025/07/24

Faculty: Ahmad Masri, MD, MS Review findings from the UK Biobank presented recently at the Peripheral Nerve Society meeting, revealing that naturally low transthyretin (TTR) levels are associated with a higher prevalence of cardiovascular biomarkers, such as NT-proBNP, and comorbidities, including peripheral arterial disease, stroke, and cognitive decline. The data suggest that low TTR may serve as a marker of broader systemic illness, both in patients with TTR amyloidosis and in the

en

00:00:00

Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy

CME/CE ·

2025/07/17

Guest: Kevin Kalinsky MD, MS Guest: Komal Jhaveri, MD, FACP This online chapterized CME activity features Drs. Kevin Kalinsky and Komal Jhaveri in a discussion on TROP2-targeted antibody-drug conjugates (ADCs) for metastatic breast cancer (mBC). The faculty describe the therapeutic role of TROP2 as well as both approved and investigational ADCs that target TROP2. Clinical trial data on TROP2-targeted ADCs from various studies are reviewed to evaluate their efficacy and safety

en

00:00:00

What Challenges and Triumphs Do Patients Face While...

CME/CE ·

2025/07/15

Host: H. James Ford, MD Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and

en

00:00:00

PROMs: Role in Clinical Research and Contributions to...

CME/CE ·

2025/07/15

Host: H. James Ford, MD Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and

en

00:00:00

Patient-Reported Outcome Measures (PROMs): Valuable...

CME/CE ·

2025/07/15

Guest: Hilary M. DuBrock, MD Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse

en

00:00:00

Managing Travel With PAH: Logistics, Medications,...

CME/CE ·

2025/07/15

Guest: Martha Kingman, DNP, FNP-C Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address

en

00:00:00

PROMs in Clinical Practice: Impacting Treatment...

CME/CE ·

2025/07/15

Guest: Jean M. Elwing, MD Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and

en

00:00:00

Aligning PAH Treatment Plans With Key Care Goals and...

CME/CE ·

2025/07/15

Guest: Jean M. Elwing, MD Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and

en

00:00:00

The Latest Patient-Centered Recommendations From the...

CME/CE ·

2025/07/15

Host: H. James Ford, MD Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and

en

00:00:00

How Do Patient Experiences and PAH Perspectives Vary...

CME/CE ·

2025/07/15

Host: H. James Ford, MD Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and

en

286 results

Similar Podcasts

科学史评话最新专辑

科学史评话

Hablando con Científicos - Cienciaes.com

cienciaes.com

天方烨谈

基因频道

The Permaculture Podcast

Scott Mann

汪诘：科学有故事（主打）

科学有故事